Cardiovascular

Featured Article
Hypertension, Hyperlipidemia for Developing and Sustaining Atrial Fibrillation
“Goal-directed use of antihypertensives and statin drugs appear to be effective strategies to reduce atrial fibrillation incidence, morbidity, and mortality,” says Mark Munger, PharmD.
Talking Therapeutics: V is for Victory in Heart Failure
In this week’s issue of Talking Therapeutics, Dr Jennings explores the science and promise of a recently approved novel medication for patients with HFrEF.
Talking Therapeutics: Targeting Inflammation to Treat Coronary Artery Disease
Dr Jennings reviews evidence supporting colchicine use to further reduce residual disease burden in coronary artery disease but highlights why pharmacists need to keep several things in mind when…

Newsfeed

Hypertension, Hyperlipidemia for Developing and Sustaining Atrial Fibrillation
Talking Therapeutics: V is for Victory in Heart Failure
Talking Therapeutics: Targeting Inflammation to Treat Coronary Artery Disease
Talking Therapeutics: Blood Pressure Potpourri
Talking Therapeutics: Making Bloody Sense of Anticoagulation in Severe COVID-19 Infections
Talking Therapeutics: Fishing for Further Reductions in Residual Cardiovascular Risk
Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Study Review Highlights How Cardiovascular Disease Affects Women and Current Gaps in Care
View More

Insights

Hypertension, Hyperlipidemia for Developing and Sustaining Atrial Fibrillation
“Goal-directed use of antihypertensives and statin drugs appear to be effective strategies to reduce atrial fibrillation incidence, morbidity, and mortality,” says Mark Munger, PharmD.
Talking Therapeutics: V is for Victory in Heart Failure
In this week’s issue of Talking Therapeutics, Dr Jennings explores the science and promise of a recently approved novel medication for patients with HFrEF.
Talking Therapeutics: Targeting Inflammation to Treat Coronary Artery Disease
Dr Jennings reviews evidence supporting colchicine use to further reduce residual disease burden in coronary artery disease but highlights why pharmacists need to keep several things in mind when dispensing colchicine to ensure that patients are…
Talking Therapeutics: Blood Pressure Potpourri
When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent and…
View More

Interactive Features

CV Deaths, Hospitalizations Reduced for Patients Treated With Farxiga
In this episode of PopHealth Perspectives, Kiersten Combs, vice president, US Cardiovascular and Metabolic Disease (US CVMD) and Naeem Khan, MD, vice president, medical, US CVMD, AstraZeneca, discuss the recent approval of Farxiga (dapagliflozin),…
Reducing Major Bleeding, CVD-Associated Deaths With Edoxaban
Robert Giugliano, MD, cardiovascular medicine specialist at Brigham and Women's Hospital, discusses the results of the ENGAGE AF-TIMI 48 trial explaining the benefits of treating patients with edoxaban, and why he encourages health care…
Mortality Rates Lowered Among NH Residents Receiving Statins as Secondary Prevention
According to study findings, older adults receiving statins after acute myocardial infarction experienced reduced 1-year mortality by what percent?
Adherence Rates Among Patients With AF Who Began Anticoagulation Therapy
Among those who receive oral anticoagulation therapy, researchers were curious about the following question: “What are the longitudinal patterns of adherence to treatment with warfarin and direct oral anticoagulants among patients with atrial…
View More
Back to Top